Clinical Trial Update: A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of encorafenib and cetuximab as a rechallenge treatment for patients with BRAF V600E-mutant metastatic color…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• BRAFTOVI (ENCORAFENIB)
• ERBITUX (cetuximab)

Snippet

Sponsor: Vall d'Hebron Institute of Oncology | Conditions: Colo-rectal Cancer | Phase 2 | Status: NOT_YET_RECRUITING